Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
申请人:SmithKline Beecham P.L.C.
公开号:US06673965B1
公开(公告)日:2004-01-06
A compound of formula (I)
wherein:
R isopropyl;
n is 0;
R1 is naphthylmethyl;
R2 is t-butyl; and
R3 is methyl;
is useful in the treatment of disorders mediated by s-CD23.